Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -4.8x - -5.3x | -5.0x |
| Selected Fwd P/E Multiple | -38.8x - -42.9x | -40.9x |
| Fair Value | €6.82 - €7.54 | €7.18 |
| Upside | -6.5% - 3.3% | -1.6% |
| Benchmarks | - | Full Ticker |
| AbCellera Biologics Inc. | - | DB:8QQ |
| OmniAb, Inc. | - | NasdaqGM:OABI |
| WuXi Biologics (Cayman) Inc. | - | DB:1FW2 |
| IQVIA Holdings Inc. | - | DB:QTS |
| Adaptive Biotechnologies Corporation | - | MUN:1HM |
| Evotec SE | - | DB:EVT |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 8QQ | OABI | 1FW2 | QTS | 1HM | EVT | |||
| DB:8QQ | NasdaqGM:OABI | DB:1FW2 | DB:QTS | MUN:1HM | DB:EVT | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | 27.1% | 48.4% | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | -0.3% | 12.4% | NM- | NM- | ||
| Latest Twelve Months | -14.3% | 3.5% | -1.3% | -1.7% | 34.0% | -128.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -150.2% | -132.2% | 27.8% | 6.8% | -121.1% | -3.7% | ||
| Prior Fiscal Year | -385.0% | -148.2% | 20.0% | 9.1% | -132.3% | -10.7% | ||
| Latest Fiscal Year | -564.8% | -235.1% | 18.0% | 8.9% | -89.1% | -24.6% | ||
| Latest Twelve Months | -726.3% | -229.1% | 18.0% | 8.6% | -74.8% | -26.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -2.8x | -4.6x | 16.1x | 13.8x | -14.8x | 1135.5x | ||
| Price / LTM Sales | 54.8x | 9.4x | 5.3x | 1.8x | 9.3x | 1.6x | ||
| LTM P/E Ratio | -7.5x | -4.1x | 29.4x | 20.8x | -12.4x | -6.1x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -12.4x | -4.1x | 29.4x | |||||
| Historical LTM P/E Ratio | -39.6x | -8.5x | 348.4x | |||||
| Selected P/E Multiple | -4.8x | -5.0x | -5.3x | |||||
| (x) LTM Net Income | (207) | (207) | (207) | |||||
| (=) Equity Value | 985 | 1,037 | 1,089 | |||||
| (/) Shares Outstanding | 177.6 | 177.6 | 177.6 | |||||
| Implied Value Range | 5.55 | 5.84 | 6.13 | |||||
| FX Rate: EUR/EUR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 5.55 | 5.84 | 6.13 | 7.29 | ||||
| Upside / (Downside) | -23.9% | -19.9% | -15.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 8QQ | OABI | 1FW2 | QTS | 1HM | EVT | |
| Value of Common Equity | 1,232 | 239 | 98,872 | 27,505 | 1,664 | 1,295 | |
| (/) Shares Outstanding | 298.5 | 122.3 | 4,069.1 | 173.0 | 151.9 | 177.6 | |
| Implied Stock Price | 4.13 | 1.95 | 24.30 | 158.99 | 10.95 | 7.29 | |
| FX Conversion Rate to Trading Currency | 1.16 | 1.00 | 8.32 | 1.16 | 1.16 | 1.00 | |
| Implied Stock Price (Trading Cur) | 3.56 | 1.95 | 2.92 | 137.05 | 9.44 | 7.29 | |
| Trading Currency | EUR | USD | EUR | EUR | EUR | EUR | |
| FX Rate to Reporting Currency | 1.16 | 1.00 | 8.32 | 1.16 | 1.16 | 1.00 | |